+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Opportunities for the use of thrombopoietic growth factors



Opportunities for the use of thrombopoietic growth factors



Stem Cells 16 Suppl 2: 249-253



Highly lineage specific thrombopoietic factors are now available which can produce substantial increments in platelet counts and attenuate the severity of therapy induced thrombocytopenia in preclinical models and early trials in patients. These striking findings are not equivalent to proving clinical benefit to patients, however, and studies are now in progress in a variety of clinical settings. Methodologic issues which could influence the interpretation of studies using thrombopoietin to mitigate thrombocytopenia in patients treated for acute myeloid leukemia and following stem cell transplantation are discussed. Studies in thrombocytopenic patients with myelodysplasia, aplastic anemia, immune thrombocytopenic purpura, as well as selected platelet and stem cell donors, are also of interest. It is unclear, however, whether patients with impaired marrow function can benefit from further exogenous stimulation, and side effects must be very carefully monitored in studies with normal donors.

(PDF emailed within 0-6 h: $19.90)

Accession: 046870106

Download citation: RISBibTeXText

PMID: 11012197

DOI: 10.1002/stem.5530160728


Related references

New thrombopoietic growth factors. Clinical Lymphoma & Myeloma 9 Suppl 3: S347-S356, 2010

Toxicities of the thrombopoietic growth factors. Seminars in Hematology 47(3): 289-298, 2011

Thrombopoietic growth factors and cytokines. Current Hematology Reports 4(2): 137-144, 2005

Potential clinical applications of thrombopoietic growth factors. Kuter, D J, Hunt, P, Sheridan, W, Zucker-Franklin, D Thrombopoiesis and thrombopoietins: Molecular, cellular, preclinical, and clinical biology: 79-91, 1997

Biologic and structural differences of thrombopoietic growth factors. Seminars in Hematology 37(2 Suppl 4): 19-27, 2000

Effect of gravity change on the production of thrombopoietic growth factors. Uchu Seibutsu Kagaku 15(3): 302-303, 2002

Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Critical Reviews in Oncology/Hematology 77(3): 172-183, 2011

Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin. Hematology 4(4): 335-343, 2001

Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. Current Gastroenterology Reports 11(1): 5-14, 2009

Thrombopoietic growth factors Do they have a role in myelosuppressive therapy for hematological malignancies?. Annals of Hematology 77(SUPPL 2): S93, 1998

Growth models and environmental factors: opportunities and limits in modelling forest growth. Forst und Holz 59(10): 480-484, 2004

Thrombopoietic activity of recombinant hemopoietic factors. Journal of Cellular Biochemistry Supplement 0(17 PART B): 70, 1993

A hypertransfused mouse assay for thrombopoietic factors. Blood 42(3): 423-428, 1973

Thrombopoietic factors potentially useful in the treatment of acute leukemia. Leukemia Research 22(12): 1155-1164, 1998

Evaluation of some thrombopoietic factors in thrombocytopenic patients with HCV infection. British Journal of Haematology 102(1): 170, July 1, 1998